Search
-
NewORYZON reports financial results and corporate update for quarter ended March 31st, 2026
Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off.
-
NewVIVEbiotech and Zelluna Partnership to Advance Off-the Shelf TCR-NK Cell Therapy with GMP ...
Partnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo lentiviral vectors for the advanced therapies sector.
-
NewVIVEbiotech Expands Lentiviral Vector Manufacturing Capabilities with EvoLVcell
Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve vector quality, and low batch variability.
-
NewAseBio calls for a Biotech Act I with greater funding, regulatory agility, and a stronger ...
We welcome the Biotech Act I, but believe its ambition and level of specificity must be strengthened to ensure a real impact on funding, industrial scale-up, and biotechnology innovation in Europe; a
-
Press releaseAseBio calls for a Biotech Act I with greater funding, regulatory agility, and a stronger ...
We welcome the overall regulatory proposal, but believe it requires greater ambition, specificity, and implementation capacity. We advocate for a Biotech Act I that genuinely improves access to
-
NewRubén Pérez-Mañanes: “A public hospital can sustain a regulated, multidisciplinary and s...
Rubén Pérez-Mañanes is an orthopaedic oncology surgeon at the HGUGM (Gregorio Marañón University General Hospital), deputy director of the Gregorio Marañón Health Research Institute and an ANECA
-
New#NewAseBioMember | "AseBio is a key meeting point for the Spanish biotechnology ecosystem,...
Meet StablePharma, our new member. We spoke with Lorena Carmona Rodríguez, Lab Manager/Senior Scientist.
-
NewORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemi...
In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12
-
CompanyMICROBIOMA
-
CompanyPOLAR NANOPHARMA
-
NewFor the first time, four therapeutic genes have been inserted and one ‘unwanted’ gene rem...
These results come from a preclinical study conducted by the Cell Engineering team at Integra Therapeutics using the FiCAT gene-writing platform.
-
EventMaking Pharma Spain 2027
-
New#NewAseBioMember | "It is the main meeting point for the biotech ecosystem in Spain, conne...
Meet AllBiotech, our new member. We spoke with Pablo Goñi, CEO.
-
-
EventRESI San Diego 2026
-
NewNatac unveils Oleomind, an olive extract for cognitive and mental well-being
The company presented its new Branded Ingredient at Vitafoods Europe, the nutraceutical industry trade show, which took place this week in Barcelona
-
-
CompanySYMBIONTICS DEVELOPMENTS
-
NewNode I opens at Málaga TechPark, Kadans Science Partner’s new building in Spain
The Dutch company is bolstering Málaga’s advanced technology ecosystem with a total investment of €32 million.
-
NewInstitutional architecture for innovation in healthcare: talent, networks and translation...
Innovation in healthcare does not arise solely from good ideas, but from an institutional architecture capable of attracting talent, coordinating capabilities and accelerating translation.
-
NewThe IIBB-CSIC and Chemotargets promote the development of new therapies against cancer t...
The agreement combines the preclinical models developed by the Institute of Biomedical Research of Barcelona (IIBB-CSIC) with the computational design platform of the company Chemotargets, based at
